Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Lucentis receives FDA approval for treatment of diabetic macular edema

The U.S. Food and Drug Administration today approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.

10 Aug 2012

Worldwide data reveal gaps in elderly eye care

Worldwide eye examination rates among older adults are very low, despite this age group being recommended to have an eye test at least every 1–2 years, say researchers from Canada.

10 Aug 2012

Planarian flatworms now a model system for studying eye development and eye diseases

Planarian flatworms have come under intense study for their renowned ability to regenerate any missing body part, even as adults. But now they may take on a starring role as a model system for studying eye development and eye diseases in vertebrates, including humans.

3 Aug 2012

High maternal choline intake may reduce risk of hypertension and diabetes in babies

New research from Cornell University indicates that pregnant women who increase choline intake in the third trimester of pregnancy may reduce the risk of the baby developing metabolic and chronic stress-related diseases like high blood pressure and diabetes later in life.

2 Aug 2012

Dosimetry data from SalutarisMD episcleral brachytherapy device clinical study on wet AMD

At the American Association of Physicists in Medicine (AAPM) Annual Meeting yesterday, Russell J. Hamilton, PhD, Professor and Physics Section Head, University of Arizona Department of Radiation Oncology, reviewed dosimetry data for a minimally invasive episcleral brachytherapy device developed by Salutaris Medical Devices, Inc. (SalutarisMD) to treat Wet AMD (Age-related Macular Degeneration), the leading cause of vision loss and blindness.

30 Jul 2012

ACT receives Australian patent for human retinal pigment epithelial cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued a patent in Australia, patent number 2005325753, "Improved modalities for the treatment of degenerative diseases of the retina."

28 Jul 2012

Rapamycin improves function and extends survival in mice with DCM and rare muscular dystrophies

Rapamycin, an immunosuppressant drug used in a variety of disease indications and under study in aging research labs around the world, improved function and extended survival in mice suffering from a genetic mutation which leads to dilated cardiomyopathy (DCM) and rare muscular dystrophies in humans.

26 Jul 2012

AAQ chemical temporarily restores vision in blind mice

A team of University of California, Berkeley, scientists in collaboration with researchers at the University of Munich and University of Washington in Seattle has discovered a chemical that temporarily restores some vision to blind mice, and is working on an improved compound that may someday allow people with degenerative blindness to see again.

26 Jul 2012

AHAF announces glaucoma and macular degeneration research grants

The American Health Assistance Foundation, a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world.

26 Jul 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2012 and provided an update on development programs.

25 Jul 2012

Microneedles can deliver drug formulations into the eye

Thanks to tiny microneedles, eye doctors may soon have a better way to treat diseases such as macular degeneration that affect tissues in the back of the eye. That could be important as the population ages and develops more eye-related illnesses - and as pharmaceutical companies develop new drugs that otherwise could only be administered by injecting into the eye with a hypodermic needle.

24 Jul 2012

Tiny microneedles to treat macular degeneration

23 Jul 2012

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI).

23 Jul 2012

Number of blind persons decline in Germany

The numbers of people in Germany who are blind or visually impaired is going down. Robert P. Finger and his co-authors present their findings in the current edition of Deutsches -rzteblatt International.

21 Jul 2012

RPB awards $110,000 grant to Mass. Eye and Ear and HMS for research into blinding diseases

Research to Prevent Blindness (RPB) has awarded a grant of $110,000 to the Massachusetts Eye and Ear Infirmary to support research into the causes, treatment and prevention of blinding diseases. The research will be directed by Joan W. Miller, M.D., Chief of the Mass. Eye and Ear and Mass. General Hospital's Departments of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School.

21 Jul 2012

Otsuka, Acucela commence rebamipide ophthalmic suspension Phase 3 trial in dry eye syndrome

Acucela Inc., a clinical stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced the initiation of a Phase 3 clinical trial to evaluate rebamipide ophthalmic suspension in patients with dry eye syndrome.

19 Jul 2012

ACT treats fourth patient in U.S. clinical trial for Stargardt's Macular Dystrophy

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).

13 Jul 2012

Nottingham researchers to lead Avastin clinical study for AMD

Nottingham researchers are leading a study to test the effectiveness of a controversial drug in the treatment of a common loss of vision.

12 Jul 2012

As needed ranibizumab effective for exudative AMD

Study findings suggest that ranibizumab significantly improves visual acuity in patients with exudative age-related macular degeneration when administered initially on a monthly basis and followed by re-treatment if needed.

10 Jul 2012

Senior citizens report fewer visual impairment problems than their counterparts

Today's senior citizens are reporting fewer visual impairment problems than their counterparts from a generation ago, according to a new Northwestern Medicine study. Improved techniques for cataract surgery and a reduction in the prevalence of macular degeneration may be the driving forces behind this change, the researchers said.

29 Jun 2012

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Lucentis receives FDA approval for treatment of diabetic macular edema

Worldwide data reveal gaps in elderly eye care

Planarian flatworms now a model system for studying eye development and eye diseases

High maternal choline intake may reduce risk of hypertension and diabetes in babies

Dosimetry data from SalutarisMD episcleral brachytherapy device clinical study on wet AMD

ACT receives Australian patent for human retinal pigment epithelial cells

Rapamycin improves function and extends survival in mice with DCM and rare muscular dystrophies

AAQ chemical temporarily restores vision in blind mice

AHAF announces glaucoma and macular degeneration research grants

Regeneron reports total revenues of $304 million for second quarter 2012

Microneedles can deliver drug formulations into the eye

Tiny microneedles to treat macular degeneration

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

Number of blind persons decline in Germany

RPB awards $110,000 grant to Mass. Eye and Ear and HMS for research into blinding diseases

Otsuka, Acucela commence rebamipide ophthalmic suspension Phase 3 trial in dry eye syndrome

ACT treats fourth patient in U.S. clinical trial for Stargardt's Macular Dystrophy

Nottingham researchers to lead Avastin clinical study for AMD

As needed ranibizumab effective for exudative AMD

Senior citizens report fewer visual impairment problems than their counterparts

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in